In this study, we hypothesized that total flavonoid of Litsea coreana leve （TFLC） protects against focal cerebral ischemia/reperfusion injury. TFLC （25, 50, 100 mg/kg） was administered orally to a rat model of foc...In this study, we hypothesized that total flavonoid of Litsea coreana leve （TFLC） protects against focal cerebral ischemia/reperfusion injury. TFLC （25, 50, 100 mg/kg） was administered orally to a rat model of focal ischemia/reperfusion injury, while the free radical scavenging agent, edaravone, was used as a positive control drug. Results of neurological deficit scoring, 2,3,5-triphenyl tetrazolium chloride staining, hematoxylin-eosin staining and biochemical tests showed that TFLC at different doses significantly alleviated cerebral ischemia-induced neurological deficits and histopathological changes, and reduced infarct volume. Moreover, it suppressed the increase in the levels of nitrates plus nitrites, malondialdehyde and lactate dehydrogenase, and it diminished the reduction in glu- tathione, superoxide dismutase and catalase activities induced by cerebral ischemia/reperfusion injury. Compared with edaravone, the protective effects of TFLC at low and medium doses （25, 50 mg/kg） against cerebral ischemia/reperfusion injury were weaker, while the protective effects at high dose （100 mg/kg） were similar. Our experimental findings suggest that TFLC exerts neuroprotective effects against focal cerebral ischemia/reperfusion injury in rats, and that the effects may be asso- ciated with its antioxidant activities.展开更多
基金supported by the National Natural Science Foundation of China,No.81001457,81072686University Scientific Research Projects of Anhui Province in China,No.KJ2012B104Key Program of University Scientific Research Projects of Anhui Province in China,No.2006kj095A
文摘In this study, we hypothesized that total flavonoid of Litsea coreana leve （TFLC） protects against focal cerebral ischemia/reperfusion injury. TFLC （25, 50, 100 mg/kg） was administered orally to a rat model of focal ischemia/reperfusion injury, while the free radical scavenging agent, edaravone, was used as a positive control drug. Results of neurological deficit scoring, 2,3,5-triphenyl tetrazolium chloride staining, hematoxylin-eosin staining and biochemical tests showed that TFLC at different doses significantly alleviated cerebral ischemia-induced neurological deficits and histopathological changes, and reduced infarct volume. Moreover, it suppressed the increase in the levels of nitrates plus nitrites, malondialdehyde and lactate dehydrogenase, and it diminished the reduction in glu- tathione, superoxide dismutase and catalase activities induced by cerebral ischemia/reperfusion injury. Compared with edaravone, the protective effects of TFLC at low and medium doses （25, 50 mg/kg） against cerebral ischemia/reperfusion injury were weaker, while the protective effects at high dose （100 mg/kg） were similar. Our experimental findings suggest that TFLC exerts neuroprotective effects against focal cerebral ischemia/reperfusion injury in rats, and that the effects may be asso- ciated with its antioxidant activities.
